z-rostudirsen Updated Aug 20
The January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.
- FDA accepted the z-rostudirsen BLA with Priority Review and set a PDUFA target action date of January 21, 2027 (8-K filed July 20, 2026; Q2 2026 earnings release), putting a potential first U.S. launch in Q1 2027 within reach.
- Phase 1/2 DELIVER topline showed statistically significant dystrophin expression and functional improvement, including a statistically significant gain on the primary functional endpoint (RFF velocity) at 6 months, and 24-month data showed heart/lung function improvement vs. natural-history decline (press releases March 2026, 2026 MDA Conference).
- Wall Street is broadly positive: consensus is strong_buy (19 Buy/Strong Buy vs. 2 Hold, 0 Sell) with a mean price target of $39.40 and median $40 vs. a ~$26.78 last price (~49% implied upside).
- Approval is an Accelerated Approval based on dystrophin as a surrogate endpoint; the confirmatory FORZETTO trial is still enrolling and its success, years away, determines whether approval becomes traditional, leaving a real post-approval overhang.
- Shareholder dilution: July 2026 upsized offering of 18.3M shares at $20.50 (~$375M gross) was assessed as diluting existing holders by roughly 9-11% including the underwriter option; the Q2 2026 release also cites a $431M offering and a $400M debt facility.
- Heavy insider selling into strength: director Jason P. Rhodes (Atlas Venture) sold ~1.36M + ~478K + ~322K shares (~$54M combined reported value) on Aug 14, 2026 under a 10b5-1 plan adopted July 13, 2026, with additional insider sales by officers in July-August 2026.